Drug Trial Radar · NCT06423703
A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomy
Last checked: Nov 20, 2026Latest source record: Jan 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Jul 18, 2024
Primary completion
Jan 31, 2025
Study completion Jan 31, 2025
Sponsor
- Lead sponsor
- Tris Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- May 21, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of Cebranopadol for acute pain after a bunionectomy.
Conditions
- Acute Pain
Interventions
CebranopadolDrug
once daily for 3 days
Oxycodone IRDrug
four times per day for 3 days
Placebo OnlyDrug
four times per day for 3 days
PlaceboDrug
three times per day for 3 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pain NRS area under the curve: cebranopadol vs. placeboTime frame: 2-48 hours
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
ALLEVIATE 2 Site 001108
Sheffield, Alabama
ALLEVIATE 2 Site 001106
Little Rock, Arkansas
ALLEVIATE 2 Site 001103
Tampa, Florida
ALLEVIATE 2 Site 001102
Atlanta, Georgia
ALLEVIATE 2 Site 001107
Overland Park, Kansas
ALLEVIATE 2 Site 001105
Pasadena, Maryland
Alleviate 2 001113
Houston, Texas
ALLEVIATE 2 Site 001104
McAllen, Texas
ALLEVIATE 2 Site 001111
San Antonio, Texas
ALLEVIATE 2 Site 001101
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.